Minimally invasive robot-B (02252) rose nearly 20% in the intraday period. As of press release, it was up 15.7% to HK$15.18, with a turnover of HK$6.086 million.
The Zhitong Finance App learned that minimally invasive robot-B (02252) rose nearly 20% in the intraday period. As of press release, it had risen 15.7% to HK$15.18, with a turnover of HK$6.086 million.
According to the news, Minimally Invasive Robotics announced on March 5 that its annual revenue is expected to increase by more than 350% year on year. This increase is mainly due to the continuous increase in sales revenue due to the comprehensive commercialization process of the Group's products Tumai quadrilateral endoscopic surgery robot, Honghu joint replacement surgery robot, and Dragonfly Eye 3D electronic laparoscopy. The net loss for 2023 is expected to be no more than RMB 1.05 billion, compared with RMB 1,146 billion in the previous year.
Furthermore, recently, Tumai's four-arm endoscopic surgery robot successfully assisted in carrying out a radical prostate cancer surgery overseas. This operation is the first international human clinical operation carried out by a domestic endoscopic surgical robot, which means that a domestic surgical robot has opened up overseas markets. CITIC Construction Investment previously indicated that a new batch of surgical robot configuration plans have been released, and minimally invasive robots are expected to seize policy opportunities and rapidly scale up.